Page 74 - May-June 2025 Life In Naples Magazing

NCH Rooney Heart Institute Leads

Successful Clinical Trial for Groundbreaking

Cardiac Ablation Technology

by Paul Hiltz, NCH President & CEO
am excited to announce that the The Affera system’s ability to seamlessly combine mapping and
NCH Rooney Heart Institute has dual-energy ablation has proven to be a transformative tool for
a
I chieved a significant milestone with treating patients with persistent AF. The results showed notable
the successful completion of a clinical improvements in procedural efficiency and faster recovery times,
trial evaluating the Affera™ Mapping and further solidifying NCH’s commitment to providing cutting-edge
Ablation System, featuring the Sphere-9™ cardiovascular care.
Catheter. As one of only two sites in Florida The recent approval of the Affera Mapping and Ablation
to offer this innovative technology, NCH System with the Sphere-9™ Catheter by the U.S. Food and
continues to lead the way in advancing cardiac care. Drug Administration (FDA) underscores the positive outcomes
Designed to enhance the treatment of atrial fibrillation observed during clinical trials, including those conducted at NCH.
(AF) and other complex cardiac arrhythmias, the Affera With this achievement, the NCH Rooney Heart Institute
system integrates high-density mapping with dual-energy continues to establish itself as a leader in advanced heart rhythm
ablation capabilities. By offering both pulsed field (PF) and treatments. This milestone not only benefits the local community
radiofrequency (RF) energies, the platform allows for precise, but also contributes to the broader field of electrophysiology.
patient-specific treatment that improves outcomes and For more information on the NCH Rooney Heart
procedural efficiency. Institute’s commitment to advancing cardiovascular care,
Led by Dinesh Sharma, MD, the trial demonstrated
visit NCHMD.org
the system’s safety and effectiveness, representing a major
advancement in electrophysiology care.

74 www.LifeInNaples.net